Drug-related TEAEs occurring in more than 1 patient in any cohort (safety population)
| n (%) . | Mezagitamab cohort . | ||||||
|---|---|---|---|---|---|---|---|
| 45 mg (n = 4) . | 135 mg (n = 3) . | 300 mg (n = 12) . | 600 mg (n = 22) . | 1200 mg (n = 3) . | PomDex (n = 6) . | Total (N = 50) . | |
| Hematologic | |||||||
| Neutropenia∗ | 1 (25) | 0 | 1 (8) | 2 (9) | 1 (33) | 1 (17) | 6 (12) |
| Neutrophil count decreased∗ | 1 (25) | 0 | 0 | 0 | 0 | 3 (50) | 4 (8) |
| Anemia | 0 | 1 (33) | 2 (17) | 1 (5) | 0 | 0 | 4 (8) |
| Leukopenia | 1 (25) | 2 (67) | 0 | 1 (5) | 0 | 0 | 4 (8) |
| Nonhematologic | |||||||
| Fatigue | 1 (25) | 1 (33) | 2 (17) | 4 (18) | 1 (33) | 1 (17) | 10 (20) |
| URT infection | 0 | 0 | 1 (8) | 3 (14) | 1 (33) | 1 (17) | 6 (12) |
| Diarrhea | 0 | 0 | 0 | 2 (9) | 1 (33) | 1 (17) | 4 (8) |
| Nausea | 0 | 0 | 2 (17) | 1 (5) | 0 | 0 | 3 (6) |
| Headache | 0 | 0 | 1 (8) | 2 (9) | 0 | 0 | 3 (6) |
| Pneumonia | 0 | 0 | 0 | 2 (9) | 0 | 0 | 2 (4) |
| Blood alkaline phosphatase increased | 0 | 0 | 0 | 2 (9) | 0 | 0 | 2 (4) |
| n (%) . | Mezagitamab cohort . | ||||||
|---|---|---|---|---|---|---|---|
| 45 mg (n = 4) . | 135 mg (n = 3) . | 300 mg (n = 12) . | 600 mg (n = 22) . | 1200 mg (n = 3) . | PomDex (n = 6) . | Total (N = 50) . | |
| Hematologic | |||||||
| Neutropenia∗ | 1 (25) | 0 | 1 (8) | 2 (9) | 1 (33) | 1 (17) | 6 (12) |
| Neutrophil count decreased∗ | 1 (25) | 0 | 0 | 0 | 0 | 3 (50) | 4 (8) |
| Anemia | 0 | 1 (33) | 2 (17) | 1 (5) | 0 | 0 | 4 (8) |
| Leukopenia | 1 (25) | 2 (67) | 0 | 1 (5) | 0 | 0 | 4 (8) |
| Nonhematologic | |||||||
| Fatigue | 1 (25) | 1 (33) | 2 (17) | 4 (18) | 1 (33) | 1 (17) | 10 (20) |
| URT infection | 0 | 0 | 1 (8) | 3 (14) | 1 (33) | 1 (17) | 6 (12) |
| Diarrhea | 0 | 0 | 0 | 2 (9) | 1 (33) | 1 (17) | 4 (8) |
| Nausea | 0 | 0 | 2 (17) | 1 (5) | 0 | 0 | 3 (6) |
| Headache | 0 | 0 | 1 (8) | 2 (9) | 0 | 0 | 3 (6) |
| Pneumonia | 0 | 0 | 0 | 2 (9) | 0 | 0 | 2 (4) |
| Blood alkaline phosphatase increased | 0 | 0 | 0 | 2 (9) | 0 | 0 | 2 (4) |
PomDex was given in combination with mezagitamab 300 mg (administered per the product label).
URT, upper respiratory tract.
Numbers for these preferred terms were pooled as neutropenia in the manuscript text.